Funding for this research was provided by:
European Molecular Biology Organization (ALTF 263‐2018)
Received: 16 June 2020
Accepted: 7 January 2021
First Online: 22 February 2021
: The clinical trial was an investigator-initiated study (IIS); as such, Y.C. acted as sponsor for the study. The IIS was approved by Amgen, who provided funding and supply of the clinical drug CFZ. Y.C. is a consultant for Janssen, Amgen, Neopharm, Takeda and Madison. A patent application has been filed related to this work. The other authors declare no competing interests.